Cargando…
Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium
BACKGROUND: This study seeks to evaluate the impact of breast cancer (BRCA) gene status on tumor dissemination pattern, surgical outcome and survival in a multicenter cohort of paired primary ovarian cancer (pOC) and recurrent ovarian cancer (rOC). PATIENTS AND METHODS: Medical records and follow-up...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9726811/ https://www.ncbi.nlm.nih.gov/pubmed/36085390 http://dx.doi.org/10.1245/s10434-022-12459-3 |
_version_ | 1784844870817415168 |
---|---|
author | Glajzer, Jacek Castillo-Tong, Dan Cacsire Richter, Rolf Vergote, Ignace Kulbe, Hagen Vanderstichele, Adriaan Ruscito, Ilary Trillsch, Fabian Mustea, Alexander Kreuzinger, Caroline Gourley, Charlie Gabra, Hani Taube, Eliane T. Dorigo, Oliver Horst, David Keunecke, Carlotta Baum, Joanna Angelotti, Timothy Sehouli, Jalid Braicu, Elena Ioana |
author_facet | Glajzer, Jacek Castillo-Tong, Dan Cacsire Richter, Rolf Vergote, Ignace Kulbe, Hagen Vanderstichele, Adriaan Ruscito, Ilary Trillsch, Fabian Mustea, Alexander Kreuzinger, Caroline Gourley, Charlie Gabra, Hani Taube, Eliane T. Dorigo, Oliver Horst, David Keunecke, Carlotta Baum, Joanna Angelotti, Timothy Sehouli, Jalid Braicu, Elena Ioana |
author_sort | Glajzer, Jacek |
collection | PubMed |
description | BACKGROUND: This study seeks to evaluate the impact of breast cancer (BRCA) gene status on tumor dissemination pattern, surgical outcome and survival in a multicenter cohort of paired primary ovarian cancer (pOC) and recurrent ovarian cancer (rOC). PATIENTS AND METHODS: Medical records and follow-up data from 190 patients were gathered retrospectively. All patients had surgery at pOC and at least one further rOC surgery at four European high-volume centers. Patients were divided into one cohort with confirmed mutation for BRCA1 and/or BRCA2 (BRCAmut) and a second cohort with BRCA wild type or unknown (BRCAwt). Patterns of tumor presentation, surgical outcome and survival data were analyzed between the two groups. RESULTS: Patients with BRCAmut disease were on average 4 years younger and had significantly more tumor involvement upon diagnosis. Patients with BRCAmut disease showed higher debulking rates at all stages. Multivariate analysis showed that only patient age had significant predictive value for complete tumor resection in pOC. At rOC, however, only BRCAmut status significantly correlated with optimal debulking. Patients with BRCAmut disease showed significantly prolonged overall survival (OS) by 24.3 months. Progression-free survival (PFS) was prolonged in the BRCAmut group at all stages as well, reaching statistical significance during recurrence. CONCLUSIONS: Patients with BRCAmut disease showed a more aggressive course of disease with earlier onset and more extensive tumor dissemination at pOC. However, surgical outcome and OS were significantly better in patients with BRCAmut disease compared with patients with BRCAwt disease. We therefore propose to consider BRCAmut status in regard to patient selection for cytoreductive surgery, especially in rOC. |
format | Online Article Text |
id | pubmed-9726811 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-97268112022-12-08 Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium Glajzer, Jacek Castillo-Tong, Dan Cacsire Richter, Rolf Vergote, Ignace Kulbe, Hagen Vanderstichele, Adriaan Ruscito, Ilary Trillsch, Fabian Mustea, Alexander Kreuzinger, Caroline Gourley, Charlie Gabra, Hani Taube, Eliane T. Dorigo, Oliver Horst, David Keunecke, Carlotta Baum, Joanna Angelotti, Timothy Sehouli, Jalid Braicu, Elena Ioana Ann Surg Oncol Gynecologic Oncology BACKGROUND: This study seeks to evaluate the impact of breast cancer (BRCA) gene status on tumor dissemination pattern, surgical outcome and survival in a multicenter cohort of paired primary ovarian cancer (pOC) and recurrent ovarian cancer (rOC). PATIENTS AND METHODS: Medical records and follow-up data from 190 patients were gathered retrospectively. All patients had surgery at pOC and at least one further rOC surgery at four European high-volume centers. Patients were divided into one cohort with confirmed mutation for BRCA1 and/or BRCA2 (BRCAmut) and a second cohort with BRCA wild type or unknown (BRCAwt). Patterns of tumor presentation, surgical outcome and survival data were analyzed between the two groups. RESULTS: Patients with BRCAmut disease were on average 4 years younger and had significantly more tumor involvement upon diagnosis. Patients with BRCAmut disease showed higher debulking rates at all stages. Multivariate analysis showed that only patient age had significant predictive value for complete tumor resection in pOC. At rOC, however, only BRCAmut status significantly correlated with optimal debulking. Patients with BRCAmut disease showed significantly prolonged overall survival (OS) by 24.3 months. Progression-free survival (PFS) was prolonged in the BRCAmut group at all stages as well, reaching statistical significance during recurrence. CONCLUSIONS: Patients with BRCAmut disease showed a more aggressive course of disease with earlier onset and more extensive tumor dissemination at pOC. However, surgical outcome and OS were significantly better in patients with BRCAmut disease compared with patients with BRCAwt disease. We therefore propose to consider BRCAmut status in regard to patient selection for cytoreductive surgery, especially in rOC. Springer International Publishing 2022-09-09 2023 /pmc/articles/PMC9726811/ /pubmed/36085390 http://dx.doi.org/10.1245/s10434-022-12459-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Gynecologic Oncology Glajzer, Jacek Castillo-Tong, Dan Cacsire Richter, Rolf Vergote, Ignace Kulbe, Hagen Vanderstichele, Adriaan Ruscito, Ilary Trillsch, Fabian Mustea, Alexander Kreuzinger, Caroline Gourley, Charlie Gabra, Hani Taube, Eliane T. Dorigo, Oliver Horst, David Keunecke, Carlotta Baum, Joanna Angelotti, Timothy Sehouli, Jalid Braicu, Elena Ioana Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium |
title | Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium |
title_full | Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium |
title_fullStr | Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium |
title_full_unstemmed | Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium |
title_short | Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium |
title_sort | impact of brca mutation status on tumor dissemination pattern, surgical outcome and patient survival in primary and recurrent high-grade serous ovarian cancer: a multicenter retrospective study by the ovarian cancer therapy-innovative models prolong survival (octips) consortium |
topic | Gynecologic Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9726811/ https://www.ncbi.nlm.nih.gov/pubmed/36085390 http://dx.doi.org/10.1245/s10434-022-12459-3 |
work_keys_str_mv | AT glajzerjacek impactofbrcamutationstatusontumordisseminationpatternsurgicaloutcomeandpatientsurvivalinprimaryandrecurrenthighgradeserousovariancanceramulticenterretrospectivestudybytheovariancancertherapyinnovativemodelsprolongsurvivaloctipsconsortium AT castillotongdancacsire impactofbrcamutationstatusontumordisseminationpatternsurgicaloutcomeandpatientsurvivalinprimaryandrecurrenthighgradeserousovariancanceramulticenterretrospectivestudybytheovariancancertherapyinnovativemodelsprolongsurvivaloctipsconsortium AT richterrolf impactofbrcamutationstatusontumordisseminationpatternsurgicaloutcomeandpatientsurvivalinprimaryandrecurrenthighgradeserousovariancanceramulticenterretrospectivestudybytheovariancancertherapyinnovativemodelsprolongsurvivaloctipsconsortium AT vergoteignace impactofbrcamutationstatusontumordisseminationpatternsurgicaloutcomeandpatientsurvivalinprimaryandrecurrenthighgradeserousovariancanceramulticenterretrospectivestudybytheovariancancertherapyinnovativemodelsprolongsurvivaloctipsconsortium AT kulbehagen impactofbrcamutationstatusontumordisseminationpatternsurgicaloutcomeandpatientsurvivalinprimaryandrecurrenthighgradeserousovariancanceramulticenterretrospectivestudybytheovariancancertherapyinnovativemodelsprolongsurvivaloctipsconsortium AT vandersticheleadriaan impactofbrcamutationstatusontumordisseminationpatternsurgicaloutcomeandpatientsurvivalinprimaryandrecurrenthighgradeserousovariancanceramulticenterretrospectivestudybytheovariancancertherapyinnovativemodelsprolongsurvivaloctipsconsortium AT ruscitoilary impactofbrcamutationstatusontumordisseminationpatternsurgicaloutcomeandpatientsurvivalinprimaryandrecurrenthighgradeserousovariancanceramulticenterretrospectivestudybytheovariancancertherapyinnovativemodelsprolongsurvivaloctipsconsortium AT trillschfabian impactofbrcamutationstatusontumordisseminationpatternsurgicaloutcomeandpatientsurvivalinprimaryandrecurrenthighgradeserousovariancanceramulticenterretrospectivestudybytheovariancancertherapyinnovativemodelsprolongsurvivaloctipsconsortium AT musteaalexander impactofbrcamutationstatusontumordisseminationpatternsurgicaloutcomeandpatientsurvivalinprimaryandrecurrenthighgradeserousovariancanceramulticenterretrospectivestudybytheovariancancertherapyinnovativemodelsprolongsurvivaloctipsconsortium AT kreuzingercaroline impactofbrcamutationstatusontumordisseminationpatternsurgicaloutcomeandpatientsurvivalinprimaryandrecurrenthighgradeserousovariancanceramulticenterretrospectivestudybytheovariancancertherapyinnovativemodelsprolongsurvivaloctipsconsortium AT gourleycharlie impactofbrcamutationstatusontumordisseminationpatternsurgicaloutcomeandpatientsurvivalinprimaryandrecurrenthighgradeserousovariancanceramulticenterretrospectivestudybytheovariancancertherapyinnovativemodelsprolongsurvivaloctipsconsortium AT gabrahani impactofbrcamutationstatusontumordisseminationpatternsurgicaloutcomeandpatientsurvivalinprimaryandrecurrenthighgradeserousovariancanceramulticenterretrospectivestudybytheovariancancertherapyinnovativemodelsprolongsurvivaloctipsconsortium AT taubeelianet impactofbrcamutationstatusontumordisseminationpatternsurgicaloutcomeandpatientsurvivalinprimaryandrecurrenthighgradeserousovariancanceramulticenterretrospectivestudybytheovariancancertherapyinnovativemodelsprolongsurvivaloctipsconsortium AT dorigooliver impactofbrcamutationstatusontumordisseminationpatternsurgicaloutcomeandpatientsurvivalinprimaryandrecurrenthighgradeserousovariancanceramulticenterretrospectivestudybytheovariancancertherapyinnovativemodelsprolongsurvivaloctipsconsortium AT horstdavid impactofbrcamutationstatusontumordisseminationpatternsurgicaloutcomeandpatientsurvivalinprimaryandrecurrenthighgradeserousovariancanceramulticenterretrospectivestudybytheovariancancertherapyinnovativemodelsprolongsurvivaloctipsconsortium AT keuneckecarlotta impactofbrcamutationstatusontumordisseminationpatternsurgicaloutcomeandpatientsurvivalinprimaryandrecurrenthighgradeserousovariancanceramulticenterretrospectivestudybytheovariancancertherapyinnovativemodelsprolongsurvivaloctipsconsortium AT baumjoanna impactofbrcamutationstatusontumordisseminationpatternsurgicaloutcomeandpatientsurvivalinprimaryandrecurrenthighgradeserousovariancanceramulticenterretrospectivestudybytheovariancancertherapyinnovativemodelsprolongsurvivaloctipsconsortium AT angelottitimothy impactofbrcamutationstatusontumordisseminationpatternsurgicaloutcomeandpatientsurvivalinprimaryandrecurrenthighgradeserousovariancanceramulticenterretrospectivestudybytheovariancancertherapyinnovativemodelsprolongsurvivaloctipsconsortium AT sehoulijalid impactofbrcamutationstatusontumordisseminationpatternsurgicaloutcomeandpatientsurvivalinprimaryandrecurrenthighgradeserousovariancanceramulticenterretrospectivestudybytheovariancancertherapyinnovativemodelsprolongsurvivaloctipsconsortium AT braicuelenaioana impactofbrcamutationstatusontumordisseminationpatternsurgicaloutcomeandpatientsurvivalinprimaryandrecurrenthighgradeserousovariancanceramulticenterretrospectivestudybytheovariancancertherapyinnovativemodelsprolongsurvivaloctipsconsortium |